Digest Network Come funziona
Network
/
Società
On
Non verificato

Onchilles Pharma

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

9 comunicati stampa

Guarda tutti i comunicati
04/06/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors
Fonte
Onchilles Pharma
Emittente
Business Wire
1.00
0
17/04/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection
Fonte
Onchilles Pharma
Emittente
Business Wire
1.00
0
17/03/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Onchilles Pharma to Present New Preclinical Data on Systemically Delivered NEU-002 Program at AACR 2026
Fonte
Onchilles Pharma
Emittente
Business Wire
1.00
0
02/02/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Onchilles Pharma Announces IND Clearance for N17350, Advancing the First Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway into the Clinic
Fonte
Onchilles Pharma
Emittente
Business Wire
1.00
0
07/11/2025
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Sanità
Oncologia
Mercato del lavoro
Industria
​​Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor
Fonte
Onchilles Pharma
Emittente
Business Wire
1.00
0
25/04/2025
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Onchilles Pharma Presents New Data at AACR 2025 Highlighting N17350, a Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway
Fonte
Onchilles Pharma
Emittente
Business Wire
1.00
0
13/01/2025
Mercato del lavoro
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Onchilles Expands Leadership Team to Advance First-in-Class Pan-Cancer Therapeutics Targeting the ELANE Pathway into Clinical Trials
Fonte
Onchilles Pharma
Emittente
Business Wire
1.00
0
07/11/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at SITC 2024
Fonte
Onchilles Pharma
Emittente
Business Wire
1.00
0
04/10/2024
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Onchilles Pharma Announces Presentation of Data for the NEU-002 Program at SITC 2024
Fonte
Onchilles Pharma
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0